Monte Rosa Therapeutics logo

Monte Rosa Therapeutics

GLUE | NASDAQ
Chart Builder DCF Calculator
$9.16
-$0.21 (-2.24%)
At close: Nov 16, 2026, 4:00 PM ET
$9.16
$0.00 (0.00%)
After-hours: Nov 16, 2026, 5:56 PM ET
-2.24%

Rating

Updated: Nov 16, 2026
44.2
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #411/1021 (Top 40%)

Key Statistics

Market Data

Market Cap $932.42M
1D Range
9.03 9.46
52W Range
9.03 25.31

Valuation (TTM)

PE -5.36
PB 1.88
EV/EBITDA -3.21

Valuation (NTM)

Forward PE N/A
Forward PEG -0.02
Price Target $25.00
Loading financial charts...

Profile

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms t...

Sector Healthcare
Industry Biotechnology
Employees 173
IPO Date Jun 24, 2021
Fiscal Year January - December

Latest News

Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript

2 months ago · seekingalpha.com

Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript
Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease

2 months ago · benzinga.com

Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease
Monte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet

2 months ago · seekingalpha.com

Monte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

3 months ago · globenewswire.com

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates

3 months ago · zacks.com

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?

5 months ago · fool.com

After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?
Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential

5 months ago · seekingalpha.com

Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates

6 months ago · zacks.com

Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise

7 months ago · fool.com

Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

8 months ago · zacks.com

Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Earnings

Latest Earnings
Nov 5, 2026
EPS
$0.03
Beat +113.98%
REV
$54.38M
Beat +60.58%
Next Earnings
Mar 16, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
6
Consensus
Buy
Price Target
$25.00
Upside
+172.93%
Buy (6)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.